VIGex: a VHIO-developed predictive, pan-cancer platform to help guide patient selection for personalized immunotherapy. – Vall d’Hebron Institute of Oncology

Quoting Vall d’Hebron Institute of Oncology on LinkedIn:

“VIGex: a VHIO-developed predictive, pan-cancer platform to help guide patient selection for personalized immunotherapy.

Published open access and ahead of print as a Clinical and Translational Article in the Cell Press journal Med, results of a study led by researchers of VHIO’s Cancer Genomics Lab led by Ana Vivancos Prellezo, and our Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch directed by Elena Garralda Cabanas, have preliminarily validated the VIGex gene expression signature as a tool for classifying solid tumors based on the expression level of genes involved in the adaptive immune response, and a predictor of patients’ response to immunotherapy.”

For details click here.
Source: Vall d’Hebron Institute of Oncology/LinkedIn